49 views 13 secs 0 comments

Novartis in Advanced Talks to Buy Cytokinetics

In Business
January 08, 2024

Updated Jan. 8, 2024 1:14 pm ET

Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as pharmaceutical companies companies continue to snap up fast-growing biotechs to replenish their pipelines. 

A purchase by the Swiss drug company of South San Francisco-based Cytokinetics, which has a market value of about $9 billion, could be completed as soon as this week, according to people familiar with the situation. Cytokinetics has been running a sale process and it is possible another suitor could re-emerge; there also may be no deal at all. 

Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel210520-twitter-verified-cs-70cdee.jpg (1500×750)

Support Independent Journalism with a donation (Paypal, BTC, USDT, ETH)
Avatar
/ Published posts: 43116

The latest news from the News Agencies